GILD

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+2.77%

Status

scored

Maintain the 3% GILD position (already at reduced weight from four prior Sell trim cycles) with hard stops at $138 daily close or 200 SMA breach at $135.63. No pre-earnings action despite elevated technicals and M&A concerns—the position is too small to justify further trim, which would mathematically equate to exit. Capture 2.23% dividend carry while awaiting the Q3 2026 binary catalyst, then scale to 5% on constructive print with pullback, or exit fully on technical break.

Outcome

✓

Return

+0.17%

Status

scored

Maintain GILD at modestly below benchmark weight with the 10/6 Sell-with-trim architecture already executed; do not add or trim further ahead of Q3 earnings. Structural stop sits at $141.72 daily close, while pre-committed re-engagement triggers include VWMA reclaim at $149.55 with volume and positive MACD, or a clean Q3 print with constructive guidance. Bear case thresholds (revenue <$7.5B, EPS <$1.80) would trigger reassessment toward Underweight.

Outcome

✗

Return

+1.82%

Status

scored

Trim 40-50% of GILD exposure at current $144 levels, redeploying proceeds into 4.5%+ short-duration Treasuries rather than other pharma names; maintain 50-60% residual position weight with a hard stop at $141.50 (50 SMA) on daily close. Pre-commit re-engagement triggers include 10 EMA reclaim at $147 with positive MACD histogram (50% scaled add), 50 SMA retest with MACD/RSI confirmation (50% scaled add), and full re-engagement on a clean Q3 print with constructive lenacapavir commentary, with Q3 2026 earnings in late October/early November serving as the binary re-evaluation event.

Outcome

–

Return

-0.28%

Status

scored

Sell GILD with a 30% trim into the $146-148 resistance zone, rotating proceeds into 4.5%+ short-duration Treasuries to capture the 2.3pp yield differential versus GILD's 2.27% dividend. Maintain the residual 70% position with a hard stop at $141.50 (daily close below 50 SMA structural break), and set re-engagement triggers at 10 EMA reclaim with positive MACD histogram, 50 SMA retest with MACD/RSI confirmation, or clean Q3 earnings resolution.

Outcome

–

Return

-0.08%

Status

scored

Sell rating on GILD with a 30–40% trim into the $150–152 resistance zone, redeploying proceeds into 4.5%+ short-duration Treasuries while maintaining a 60–70% residual position with a hard stop at $141.98 (50 SMA on daily close); re-engagement requires both a clean Q3 earnings print AND positive MACD histogram reset, with the rotation into T-bills capturing the 2.3 percentage-point yield differential versus the 2.2% GILD dividend.

Outcome

✓

Return

-1.87%

Status

scored

Sell GILD with 40-50% trim into the $152-$154 resistance zone, redeploying proceeds into T-bills yielding 4.5%+ rather than other pharma names with their own binary catalysts. Maintain a 30% residual with a hard stop at $142 daily close; full exit triggered by any close below $142. Re-engagement requires a clean Q3 beat-and-raise plus MACD histogram reset positive — not a pre-print reversion trade.

Outcome

✓

Return

-1.04%

Status

scored

Maintain GILD at Hold with 10-15% trim in mid-October (pre-earnings), fixing the stop from $134.94 to $140-$141 (~2.3 ATR distance below 50 SMA). Re-engage on $142-$146 pullback with MACD/RSI confirmation at 50% scaled size, or on >$154 breakout with >7M volume and MACD bullish re-cross. Hard exit only on close below $134.94; full re-evaluation at Q3 2026 earnings (late October/early November).

Outcome

✗

Return

-1.47%

Status

scored

Maintain GILD at Hold rating with a primary add zone of $148.79-$141.59 (Sep range low to 50 SMA) conditioned on MACD histogram reset positive and RSI >50 for 50% starter position; execute a 10-15% pre-earnings trim over 3-5 sessions beginning mid-October (not late October) ahead of late October/early November Q3 2026 earnings, and set structural stop at $141.59 — do NOT tighten to $147 or $145.91 as those are less than 2 ATR and would get tagged on routine mean reversion.

Outcome

–

Return

-0.61%

Status

scored

Gilead Sciences (GILD) is rated Underweight with a recommendation to trim to 40-50% of benchmark weight, executed in two staged blocks at $152 and $151-152 limit respectively. A structural stop is maintained at $141.21 (50 SMA) rather than tightening to the $147 (20 SMA) level, which sits only 1.4x ATR above current price and would be tagged on routine volatility. The position sizing and stop discipline balance participation in a potential $154.29 breakout against the asymmetric risk of the Q3 2026 earnings binary catalyst.

Outcome

✓

Return

+0.85%

Status

scored

Maintain GILD at neutral weight pending Q3 catalyst resolution; do not add at $150.93 with negative MACD histogram at multi-month resistance. Primary add location is pullback to $146-148 (better risk/reward at ~1.5:1) with secondary breakout entry above $153.86 at reduced sizing (~1% vs. 2-3%).

Outcome

✓

Return

+0.83%

Status

scored

Maintain GILD at current size without adding in the $148-$155 range, preserving the $138 structural stop (50 SMA). Stage a 10-15% pre-earnings trim beginning mid-to-late October (~2 weeks before late October/early November Q3 print). Re-engage with a 25-30% scaled starter on pullback to $140-$142 conditional on MACD histogram reset and RSI 50-55; upgrade to Overweight only on confirmed close above $155 with >10M volume and MACD bullish re-cross. Apply a 5-7 session time-stop on breakout triggers.

Outcome

✓

Return

-1.11%

Status

scored

Maintain GILD at $151 without adding or trimming, while raising the structural stop from $137 to $142.54 (lower Bollinger Band) for appropriate downside cushion at current entry levels. Stage a 10-15% pre-earnings trim over 3-5 sessions approximately 2 weeks before the late October/early November Q3 print, rather than the more aggressive 15-25% trim range. Pre-commit re-engagement triggers at $147.60-148.68 for a half-size add on pullback and $154.20+ for a confirmed breakout on >10M volume with MACD re-cross, converting the passive Hold into active capital deployment through the binary catalyst.

Outcome

✓

Return

-0.85%

Status

scored

Maintain GILD at Hold with existing positions managed via disciplined trailing stops at $148.92 (10 EMA) and hard exit at $139.71 (50 SMA). Do not initiate new exposure at $152.67 — wait instead for pullback to $144-148 zone with MACD reset confirmation (preferred, half-size) or breakout above $153.30 on ≥7M volume (alternative, full-size). Q3 2026 earnings (late October/early November) is the key validation catalyst; a clean print with deleveraging progress and lenacapavir uptake metrics could support the $155 price target within the 3-6 month horizon.

Outcome

✗

Return

+1.40%

Status

scored

Maintain the existing 50% deployed position without adding at current elevated levels ($150.56), while staging a 10-15% pre-earnings trim over 3-5 sessions beginning ~2 weeks before Q3 2026 earnings (late October/early November) to harvest binary catalyst risk. On any pullback to $145-147, add in 1/3 tranches with technical confirmation, but activate a 5-7 session time-stop to prevent indefinite paralysis.

Outcome

✓

Return

+0.30%

Status

scored

Maintain GILD at HOLD with 50% deployed position (sidelined 50% per plan). Do not add at current levels due to unfavorable 1:3.7 risk/reward math; do not trim aggressively as one rejection at $154 is not confirmed supply. Add 5-7 session time-stop on breakout trigger to prevent indefinite immobilization of sidelined capital. Next major re-evaluation at Q3 earnings (early November).

Outcome

✓

Return

-0.52%

Status

scored

Active Hold maintained at $150.89 with $151.48 as critical decision point—the 50% deployment from the 9/16 Overweight plan is validated, but fresh capital entry fails the Aggressive Analyst's own R/R test with 4% upside versus 8.1% downside to the $138.52 stop. A confirmed close above $151.48 on volume >7M with MACD bullish re-cross triggers second 50% deployment, while declining volume above that level signals distribution warranting a 10-15% trim; structural breaks below $146.96 or $138.52 trigger progressive re-rating to Underweight.

Outcome

✓

Return

+2.17%

Status

scored

Execute the scaled-in Overweight plan: deploy 50% of intended allocation at $147–148, reserve remaining 50% for a pullback to $144–146, with a hard-respected stop at $142 and a 1% portfolio-loss cap on stop-out. The structural case (14.93x forward P/E vs 16–18x peers, $9.46B FCF, 2.24% dividend, 0.35 beta, lenacapavir 4th Circuit win) supports increasing exposure, but negative MACD histogram, overhead resistance at $150.84, elevated PEG of 2.14, and asymmetric Q3 earnings risk six weeks out constrain conviction to Overweight rather than full Buy.

Outcome

✗

Return

+0.94%

Status

scored

Trim GILD position by 20% (top of validated trim band) over 3-5 sessions, front-loaded ahead of tomorrow's FOMC, selling into the $147-150 zone or accepting $146-level exits if the Fed hits before execution; park freed capital in cash and short-duration Treasuries only with no rotation into new names. Maintain the residual 80% position for the 2.24% dividend (2.4x FCF coverage), with re-engagement triggers at 10 EMA reclaim ($145.50) plus MACD turning positive within 3 sessions, or a close above $147.52 with MACD positive—do not wait for $151+ momentum repair.

Outcome

✓

Return

-0.08%

Status

scored

Maintain GILD at current core weight with no additions at $146 and no trimming into the current MACD bear cross. Pre-commit a 15% trim ahead of the Q3 earnings binary (late October/early November) to manage catalyst risk, with re-engagement triggered by 10 EMA reclaim (~$145.50) and structural stop defense at $137.74 (50 SMA).

Outcome

✗

Return

+1.87%

Status

scored

Reduce GILD to 65–70% of original core exposure by trimming an additional 15% via staged limit orders in the $145–$148 zone, honoring the validated per-event band while avoiding the destruction regime that full exits from this FCF-positive defensive franchise would trigger. Carry residual risk with a $137.74 closing-basis stop; re-evaluate at the 10 EMA reclaim ($145.50), Q2 2026 earnings (late October), or the $143 second-trim trigger.

Outcome

✓

Return

-0.75%

Status

scored

Maintain Gilead Sciences at the trimmed 80-85% core position; do not deploy new capital at $144.81 or execute additional trims within 24 hours of the 9/9 Underweight trim. Use a closing-basis stop at $137.74 (50 SMA) as the thesis-invalidating level, with staged re-entry at $137-140 on basing confirmation or faster re-engagement via 10 EMA reclaim at $145.50 or RSI 60. Re-evaluate at Q3 2026 earnings (late October/early November) for acquisition disclosure and integration read.

Outcome

–

Return

-0.58%

Status

scored

GILD is trimmed 15-20% from current levels ($145.65) to preserve 80-85% core exposure, calibrated below the research manager's 25-30% and conservative analyst's 40% magnitudes. A hard stop is set at $138 (50 SMA/lower Bollinger confluence) with a second-trim trigger at $143 close and re-engagement only on daily close above $147.52 with MACD histogram turning positive. Re-evaluate at CPI print (mid-September) and Q3 2026 earnings (late October/early November).

Outcome

✓

Return

-0.68%

Status

scored

Maintain HOLD on GILD at $146.64 without deploying new capital at current levels. Existing positions should be held with a hard stop on daily close below $136.98 (50 SMA). New capital deployment should follow a tiered approach: 50% of intended size on pullback to $142-145 with bullish reversal confirmation, and the remaining 50% on breakout above $151.48 with >7M share volume. Re-evaluate at Q3 2026 earnings (early November) given the ±8-10% binary move risk.

Outcome

✗

Return

-2.89%

Status

scored

Maintain existing GILD exposure with a trailing stop at $146 and refrain from deploying new capital at $151. The binding lesson sequence from the last three GILD decisions (9/3, 9/2, 9/1) shows Underweight trims at this stretched-but-intact-trend setup produce marginal alpha at best (+0.2%, +0.0%, -0.7%), directing future similar setups toward either a smaller trim (≤10%) or a full pass with the stop framework carrying the risk.

Outcome

✗

Return

-0.15%

Status

scored

Gilead Sciences warrants an Underweight rating at ~$153 as price approaches $155 resistance (52-week high $155.38) with MACD histogram contraction and $12.9B IPR&D impairment overhang. The 15%–20% trim (not the 25%–33% proposed by the research manager/trader) is calibrated between the prior 9/1 destruction band and 9/2 success, preserving 80%–85% core exposure to the $9.8B FCF engine and 0.34-beta defensive floor. Stop is set at $147.44 (10 EMA), tightening to $143.44 on failure, with Q3 2026 earnings as the primary re-evaluation catalyst.

Outcome

–

Return

+1.08%

Status

scored

Trim GILD by 15% at current levels ($149.50–$150.00) to a 15% Underweight position while preserving 85% core exposure, calibrated to honor the binding 9/1 lesson (≤10% or skip for defensive compounders), the new fundamental overhang ($12.9B impairment, 59% net leverage step-up from the $11.2B acquisition), and prior reflections confirming partial trims—not full exits—protect alpha in FCF-positive defensives with 0.34 beta, 2.4x dividend coverage, and $9.8B FCF.

Outcome

✓

Return

-0.21%

Status

scored

Trim GILD by 20-25% (not the research manager's 30-50% or trader's full Sell), executing in the $148-$152 zone while preserving 75-80% as core dividend/FCF exposure. The Underweight rating reflects directional caution on deteriorating technical setup (RSI decay 74→67, volume deterioration to 4.83M, $150 psychological rejection) and the $12.93B impairment exceeding the $11.21B purchase price, but the magnitude is calibrated to avoid the alpha destruction seen in full exits and heavier trims across prior decisions.

Outcome

✗

Return

+2.45%

Status

scored

Gilead Sciences is downgraded to Underweight with a 35% position reduction executed in two tranches (20% immediately at ~$148.50, 15% triggered on confirmed break below $145), while preserving a 65% core position to maintain the 2.21% dividend carry with 2.5x FCF coverage and 0.34-beta defensive ballast. The bearish thesis is supported by 1,250 bps operating margin compression over three consecutive quarters, revenue stagnation at $6.96B–$7.92B for five straight quarters, a $12.9B goodwill impairment, and valuation at 14.8x forward earnings above historical 10-13x multiples for a no-growth pharma.

Outcome

✗

Return

+0.45%

Status

scored

Trim GILD by 20-25% from current exposure, reducing the position to 75-80% of benchmark weight to capture the Aug 28 distribution signal while avoiding the alpha destruction seen in prior passive Hold decisions (-1.9% to -2.4% alpha). Hard stop at $134 (50 SMA structural invalidation) with tactical monitoring at the 10 EMA ($145.12), as the balance sheet deterioration (equity down 50%, $4B new debt, NTA at -$10.5B) warrants de-risking but FCF strength ($9.77B TTM) and the HIV franchise (10% YoY growth) argue against a full exit.

Outcome

✗

Return

-2.14%

Status

scored

Maintain GILD at 4-5% portfolio weight through the August 27 FDA catalyst without adding at $148-149 (96th percentile, RSI 69, asymmetric risk for new entrants) or further trimming (8/26 reflection showed further cuts over-shoot with -0.1% alpha). Define explicit post-FDA actions: trim 10-15% into $158-160 if approval gaps; add on pullback to $144-146 with multi-factor confirmation; invalidate on close below $132. Re-evaluate rating after Q3 2026 earnings.

Outcome

✗

Return

+0.52%

Status

scored

Gilead is rated Underweight with a 50-70% benchmark weight trim ahead of the August 27 FDA catalyst, retaining a 25-30% core position to preserve the 5.4% total shareholder yield while avoiding full exit per prior HONA/GILD reflection lessons. Risk-reward at current levels is unfavorable (0.7:1-4.3:1 downside-to-upside ratio), the stock exhibits distribution signatures into a binary event (RSI 68.26, declining volume, razor-thin $0.89 50/200 SMA spread), and the balance sheet has deteriorated materially (Net Debt +33% to $23B, equity -48%); staged execution is mandated with a $135 tactical stop and $130 hard stop.

Outcome

✓

Return

-0.46%

Status

scored

Maintain GILD at 4-5% portfolio weight through the August 27 FDA catalyst without adding at $148.77, where the 1:3 risk-reward is mathematically indefensible given RSI 69.97 and declining breakout volume at multi-year highs. The 15-25% trim already executed at $142-144 (8/20-8/21) is complete; further action would violate the 8/18 lesson against over-aggressive exits in FCF-positive compounders. Post-FDA, scale to 5% on clean approval with volume confirmation; reassess on CRL/delay/restriction.

Outcome

✓

Return

+1.38%

Status

scored

Maintain GILD at 4-5% portfolio weight through the August 27 FDA catalyst with a 25-30% trim plan into any clean post-approval strength; tighten trailing stop to $138 on label complexity or let the $132 hard stop work on rejection/delay, with full reassessment within 48 hours of either outcome.

Outcome

–

Return

+0.42%

Status

scored

Trim GILD to Underweight with a 15–20% position reduction from current levels ($146.50), as the 21% rally off the June $120.69 low has created asymmetric risk-reward (roughly 1:2.5 bearish on price-only basis) with the stock sitting on the upper Bollinger Band at $146.87 amid distribution-tape breakout. Set a trailing stop at $151.50 (≈1.3 ATR) on residual exposure and re-engage via three triggers: clean reload above $153.91 on >8M volume, pullback to $132–138 with multi-factor confirmation, or post-Q3 print validating the normalization thesis.

Outcome

✗

Return

+1.87%

Status

scored

Trim 25% of GILD at $142-144 given overbought conditions (RSI 74→63, Bollinger upper-tag at $147.60) and $11.2B acquisition overhang (cash -58%, net debt +$8.5B), while maintaining 75% residual to participate if fundamentals reassert. Re-engage at $135-138 only upon multi-factor confirmation; invalidation above $148.50 on volume >8M reverts to Hold.

Outcome

✗

Return

-2.82%

Status

scored

Maintain HOLD on GILD at $147.60 without adding; the aggressive analyst overreaches on momentum (RSI 74, 1.024× upper Bollinger, 9.4% VWMA premium) and misreads valuation (negative asymmetry at $145 average entry). The Conservative's mathematical framework is binding: from $147.60 with $131.70 stop and $157 target, risk/reward is -1.6:1. Adopt the Neutral's tiered framework: tactical stop at $143.60 (1 ATR), structural stop at $131.70 (200-SMA), first add zone at $139-142 (2.0:1 R/R), and a new runaway breakout rule—add on confirmed close above $148.97 on volume >6M shares—to prevent Hold from silently degrading into Underweight-by-default when price runs through triggers without retracing. Re-evaluate at Q3 2026 earnings.

Outcome

✗

Return

+2.90%

Status

scored

Maintain GILD at HOLD given the stretched technical setup (RSI 69.6, price 10% above 50 SMA at $130.58, Bollinger breakout at 2.7σ on below-average volume) against a genuine fundamental floor (Q2 PrEP past $1B, $3.43B FCF, appeals court ruling reinforcing HIV moat). The 2.36% dividend yield provides carry while adopting a tiered entry framework: Tier 1 add at $137-138 with stop $134, Tier 2 add at $133-134 with stop $130, with hard stop at $130.58; re-evaluate at Q3 2026 earnings in late October.

Outcome

✗

Return

+3.25%

Status

scored

Maintain a disciplined Hold on GILD with a 2-3% portfolio cap and hard stop at $132. Trim triggers at $140 on unvalidated rallies and $139.13-$139.50 at upper Bollinger Band on sub-average volume protect against distribution risk, while the 2.37% dividend yield and strong fundamental floor (32.5% operating margins, 2.4x dividend coverage) justify remaining invested rather than underweighting. Re-evaluate at Q3 2026 earnings for Yeztugo validation, acquisition disclosure, and deleveraging progress.

Outcome

✓

Return

+0.40%

Status

scored

Maintain GILD as a HOLD with a core position protected by a hard stop at $132.60 (below the 50 SMA), permitting tactical 15% additions on confirmed $135 bounces with >4M shares and adding via relaxed two-of-three criteria (volume >6M above $140, 50/200 SMA cross, or retest with higher low on >4M volume). New trim trigger activated at $140 on unvalidated rallies lacking Yeztugo Q3 or integration disclosures. The 2.37% dividend yield provides carry while awaiting Q3 2026 earnings re-evaluation for PrEP durability and deleveraging progress.

Outcome

–

Return

+0.16%

Status

scored

Analysts converge on initiating a one-third position in GILD at $138, above the upper Bollinger Band at $137.37, citing improved fundamentals (Yeztugo $1B+ quarterly print with >70% persistence, $10B trailing FCF, 14x forward P/E) but acknowledging a technically stretched entry; the phased approach caps downside at $129.50 while preserving two-thirds of dry powder for pullbacks or confirmed breakouts, targeting $144-148 over 3-6 months with Q3 2026 earnings re-evaluation.

Outcome

✓

Return

+1.67%

Status

scored

Analysts maintain HOLD on GILD, keeping existing exposure at 2-3% portfolio weight with no new positions initiated; a hard stop at $131.00 (200 SMA) anchors downside protection while the upgrade framework loosens to require either a volume-confirmed close above $137.20 (>7M shares) OR a confirmed golden cross. A new trim trigger at $140 is added for unvalidated macro-driven rallies without Yeztugo Q3 confirmation or clean integration disclosure, with re-evaluation scheduled at Q3'26 earnings in late October/early November.

Outcome

–

Return

+0.07%

Status

scored

Initiate a tiered Overweight position with a 0.5–1% starter at ~$134–136 and reserve 1.5–2% for a pullback to $130–132 or a confirmed 50 SMA/200 SMA golden cross, targeting 2–3% total weight. Primary 6-month price target is $144–148 with a hard stop at $120.69; the CPI print this week serves as the trigger for tranche two deployment, with Q3 earnings (October) as the key re-rating catalyst over a 6–12 month horizon.

Outcome

✗

Return

+2.04%

Status

scored

Trim GILD to approximately 50% of benchmark weight near $133, holding the residual with a hard stop at $128.18 and full exit before $120.69 YTD low. The 8.4% total shareholder yield (5.9% FCF + 2.46% dividend) provides a downside floor that prevents a full exit, but a death cross (50 SMA 129.48 vs 200 SMA 130.92), elevated PEG of 2.14, and MACD histogram at -0.01 at $140.60 resistance warrant reduced exposure. Re-entry requires all three technical conditions: close above $140.60 on rising volume, 50 SMA crossing above 200 SMA, and positive MACD crossover with histogram greater than 0.

Outcome

✓

Return

-0.11%

Status

scored

Maintain GILD with a hedged posture through the H2 2026 Trodelvy monotherapy readout, executing a protective put at the $125 strike (3-month, ~1.5-2% of position cost) as the core risk management action to cap tail risk on this binary catalyst. Permit a modest tactical add (25-40% of standard tranche) only if the stock defends the 200 SMA at $130.87 with MACD histogram turning positive and stable volume — the defined re-engagement trigger that prevents inert patience from forfeiting tactical opportunities.